Influenza A NP (383-391) (HLA-B27)

Cat. No.: HY-P10593: Ficha de datos Instrucciones de manejo
FAQs
Technical Support

Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research.

Para uso exclusivo en investigación. No vendemos a pacientes.

Síntesis de péptidos personalizados

Influenza A NP (383-391) (HLA-B27) Estructura química

No. CAS : 126779-14-4

Tamaño		Stock
MOQ		Minimum order quantity
50 mg		Obtener un presupuesto
100 mg		Obtener un presupuesto
250 mg		Obtener un presupuesto
Other size		Obtener un presupuesto

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Recomendaciones destacadas

•Related Small Molecules:

•Related Proteins:

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn	Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research^[1].
Peso molecular	2478.80
Fòrmula	C₁₁₇H₁₇₂N₃₀O₃₀
No. CAS	126779-14-4
Sequence	Phe-Asn-Asn-Phe-Thr-Val-Ser-Phe-Trp-Leu-Arg-Val-Pro-Lys-Val-Ser-Ala-Ser-His-Leu-Glu
Sequence Shortening	FNNFTVSFWLRVPKVSASHLE
Envío	Room temperature in continental US; may vary elsewhere.
Almacenamiento	Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación	Ficha de datos (259 KB) Instrucciones de manejo (2659 KB)
Referencias	[1]. Y Xie, et al. "Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses." Cancer Gene Therapy 20.10 (2013): 590-598. [Content Brief]